The bill H. B. No. 2025-2026 proposes the enactment of section 3902.65 of the Revised Code, which mandates that health plan issuers apply prescription drug rebates to cost-sharing requirements for covered individuals. The bill defines key terms such as "health plan issuer," "price protection rebate," and "rebate," outlining the conditions under which these rebates must be calculated. Specifically, it requires health plan issuers to calculate a covered person's cost-sharing amount for prescription drugs at the point of sale based on a price that reflects a 100% reduction of all rebates received or expected to be received.

Additionally, the bill includes provisions to ensure the confidentiality of rebate information, stating that health plan issuers and their agents must not disclose the actual amounts of rebates received. It establishes that such information is confidential and not subject to public records laws, thereby protecting the financial and competitive interests of health plan issuers. Violations of this section are classified as unfair and deceptive insurance acts, subjecting offenders to regulatory proceedings.